Alteration of gene expression during progression of hypertension-induced cardiac dysfunction in rats

Tomoyoshi Koyanagi1, Lily Y Wong, Koichi Inagaki

  • 1Dept. of Chemical and Systems Biology, Stanford Univ. School of Medicine, Stanford, CA 94305-5174, USA.

Insights

This study identifies distinct molecular markers differentiating compensatory cardiac hypertrophy from decompensated cardiac dysfunction in salt-induced hypertension models. These findings aid in understanding disease progression and developing targeted therapies.

Area of Science:

  • Cardiovascular Research
  • Molecular Biology
  • Hypertension Research

Background:

  • High-salt diet-induced hypertension in Dahl rats causes cardiac hypertrophy and dysfunction.
  • The molecular differences between compensatory hypertrophy and decompensated cardiac dysfunction remain unclear.

Purpose of the Study:

  • To identify molecular hallmarks distinguishing compensatory cardiac hypertrophy from decompensated cardiac dysfunction.
  • To compare gene expression profiles at different stages of hypertension-induced heart disease.

Main Methods:

  • Quantitative real-time PCR was used to measure mRNA levels of 93 selected genes in rat cardiac tissue.
  • Gene expression was analyzed in compensatory hypertrophy (11 wk), cardiac dysfunction (17 wk), and control groups.
  • Principal component analysis was employed to segregate animals based on disease stage.

Main Results:

  • During compensatory hypertrophy, atrial natriuretic peptide (ANP) and brain natriuretic peptide increased, while SOD2 and SERCA2a decreased.
  • In cardiac dysfunction, inducible nitric oxide synthase (NOS) and angiotensin I-converting enzyme (ACE) increased.
  • Gene expression patterns significantly differed between compensatory hypertrophy and cardiac dysfunction phases, with 22 genes showing altered expression.

Conclusions:

  • Distinct molecular signatures characterize compensatory hypertrophy and decompensated cardiac dysfunction in this hypertension model.
  • Identified gene expression changes provide potential molecular markers for disease staging.
  • Principal component analysis successfully differentiated disease stages, validating the identified molecular markers.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...